Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 42 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 15078
Sealed predictions
- FIBP in dopamine neurons, braak+0.61 (p 0.084) → +0.28 (p 0.459)receipt 15085
Swarm cases
receipt 15085: FIBP in dopamine neurons, braak
- power
- full sample +0.26 (p 0.306, n 18), 95% CI -0.24 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.27 (p 0.285, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.31 (p 0.214, n 18). could be the mix.
- skeptic
- leave-one-out range +0.14 to +0.37, sign flips 0; without severely affected donors +0.26 (p 0.306, n 18). fragile.
- cell type
- strongest in OPCs: -0.78 (p 1.3e-4, n 18) vs +0.26 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FIBP in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up FIBP · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.72 p 0.0100 (needs p < 1.5e-4)
Receipts
loading the receipts